Roth Capital Remains Positive On Curis Following The Release Of Erivedge Revenue
In a research report sent to investors, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Curis Inc. (NASDAQ:CRIS) with a $6.00 price target, as partner Roche (OTC:RHHBY) reported YE14 Erivedge total revenue of $128.8 million compared to Roth’s estimate of $112 million. U.S. Erivedge sales were $83 million compared to Roth’s estimate of $92 million and E.U. sales were $39 million compared to Roth’s estimate of $20 million.
Pantginis noted, “While U.S. sales fell short of our expectations, we are encouraged by strong E.U. sales indicative of encouraging market penetration and representing an almost two-fold higher revenue stream than our estimate. E.U. sales contributed to higher total revenues than our expectations. We believe Roche is committed to the drug, both in terms of expanding territory approvals and expansion of the clinical profile.” The analyst added, “We believe CRIS is well positioned with the continued market expansion of Erivedge and increasing visibility of the internal pipeline.”
Titan Pharmaceuticals, Inc., incorporated on February 7, 1992, is a specialty pharmaceutical company developing proprietary therapeutics for the treatment of serious medical disorders.